Primary Cells Market: By Type (Hematopoietic, Dermatocytes, Hepatocytes, Gastrointestinal, Lung, Renal, Heart, Musculoskeletal), Origin (Human Primary Cells, Animal Primary Cells), End User (Life Science Research Companies, Research Institutes, Others), and Geography

Primary Cells Market was valued at USD 1,716.8 million in 2022 and is poised to grow at a CAGR of 10.8% over 2023-2029. Primary cells in biology refers to cells directly taken from living organisms, as opposed to cell lines that have been cultured for extended period and are often used in various biological and medical research applications. The increased demand for potential cancer medicines and treatments by research institutes and companies over cell lines owing to its close resemblance to cells in living organisms, and more accurate representation of cell behavior, function, and responses to stimuli compared to immortalized cell lines. According to Worldwide Cancer Research Fund International, in 2020, an estimated 18.1 million cancer cases around the world with 9.3 million cases in men and 8.8 million in women. Furthermore, an increased need to assess the biological relevance of the toxicity of chemicals, medicines, and compounds, that assist in the detection of potential risks is anticipated to propel the market in upcoming years. Additionally, the advancements and developments in automation, single-cell analysis, and imaging technologies have created opportunities for more comprehensive and detailed studies using primary cells among researchers and drug development companies. Currently, Organ-on-a-Chip technology is becoming popular in the market and involves the recreation of organ-level functions using primary cells on microfluidic devices, enabling more accurate physiological modeling. For instance, in June 2022, CN Bio Innovations launched an organ-on-a-chip device that allows scientists to test potential drugs on living human organ models in conventional cell culture labs without the need for animal models. But the limited availability of certain cell types, and fresh samples owing to cell source limitations along with a limited lifespan in culture may hinder the market growth. However, the rise in pharmaceutical & biotechnology industries, increase in investments by government initiatives, and private firms, and improvement in infrastructure are anticipated to burgeon the market growth during the forecast years.

Primary Cells Market Key Developments

• In March 2022, Lonza launched human stem cell offerings to provide human cord blood CD34+ hematopoietic stem cells (CB-CD34+ HSCs) in large batch sizes, expanding market need.
• In May 2020, BioIVT launched high-purity Kupffer cells to its portfolio of human primary hepatic cells to support liver disease drug discovery and development.
• In June 2018, Lonza launched hepatic stellate cells, Kupffer cells and liver-derived endothelial cells to its extensive hepatocyte’s portfolio with addition of hepatic non-parenchymal cells.